Wiederkehr JC, et al. Nonspecific Hyperamylasemia: A Case Report. JOP. J Pancreas (Online) 2013 Jan 10; 14(1):74-76.

CASE REPORT

JOP. J Pancreas (Online) 2013 Jan 10; 14(1):74-76.

Nonspecific Hyperamylasemia: A Case Report

Julio Cesar Wiederkehr, Barbara A Wiederkehr, Henrique A Wiederkehr, Caroline A Carvalho

Department of Surgery, Federal University of Paraná. Curitiba, Paraná, Brazil

Abstract

Context The elevation of serum amylase and lipase are generally associated with pancreatic diseases. However they can be associated with different pathologies unrelated with amylase and lipase. Case report This paper aims to report a case of a patient diagnosed with nonspecific hyperamylasemia and warn of this possibility in the differentiation of hyperamylasemia. Conclusion The correct diagnosis of silent hyperamylasemia is important in order to determine whether there is the risk of pancreatic disease or if we are just ahead of a benign hyperenzymemia.

INTRODUCTION

The elevation of serum amylase and lipase are usually associated with pancreatic diseases. A significant elevation of serum amylase with abnormalities in the pancreas is usually a manifestation of acute pancreatitis. However, this increase may also be related to pancreatic metabolic diseases and extrapancreatic abnormalities of the pancreatic ducts like recurrence of chronic pancreatitis, diabetic ketoacidosis and chronic viral liver disease [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]. There are still other reasons unrelated to the pancreas that are associated with this disorder, such as ectopic pregnancy, mumps, HIV infection and head trauma (Table 1) [8].

Table 1. Causes of serum amylase and lipase elevations.
Amylase	Lipase
Acute pancreatitis	Acute pancreatitis
Pancreatic pseudocyst	Pancreatic pseudocyst
Chronic pancreatitis	Chronic pancreatitis
Pancreatic carcinoma	Pancreatic carcinoma
Biliary disease	Biliary disease
Intestinal occlusion/subocclusion	Intestinal occlusion/subocclusion
Intestinal ischemia Intestinal perforation Acute appendicitis Ectopic pregnancy Renal insufficiency (creatinine clearance <50 mL/min) Parotitis Macroamylasemia Ovary cyst, ovary neoplasm Lung carcinoma Diabetic ketoacidosis HIV infection Head trauma	Acute appendicitis Intestinal inflammatory disease Renal insufficiency Alcoholism Nervous anorexic/bulimic Malignant neoplasm Hepatitis C

However, Gullo et al. [11] described in 1996 a new syndrome characterized by an asymptomatic state with elevated serum levels of pancreatic enzymes and absence of pancreatic diseases, by which it was called chronic pancreatic non-pathological hyperenzymemia (CNPH).

The cause of this hyperamylasemia is not clear. Some hypotheses report that may result from a defect in the secretion of enzymes by the basolateral surface of the acinar cells [12], causing an increase in the passage of enzymes into the bloodstream, or may also be caused by changes in the Wirsung conduct by secretin stimulation [11].

This paper aims to report a case of a patient diagnosed with nonspecific hyperamylasemia/CNPH, and warn of this possibility in the differential diagnosis of hyperamylasemia.

CASE REPORT

A 31-year-old female patient had nonspecific epigastric abdominal pain. She did not report weight loss and denied abdominal pain, cramping, diarrhea or vomiting. She denied previous episodes. The patient appeared to be in good condition, the abdomen was flat, flaccid and painless; bowel sounds were normal and had no visceromegaly. She denied use of drugs and/or alcohol. On admission laboratory tests were requested which were normal except for gamma-GT 224 U/L (reference range: 11-50 U/L) and amylase 1,451 U/L (reference range: 60-180 U/L) (Table 2) [13].

Table 2. Complementary exams.
Indicators	Patient	Reference
Total bilirubin (mg/dL)	0.83	0.3-1.0
Direct bilirubin (mg/dL)	0.58	0-0.3
Indirect bilirubin (mg/dL)	1.25	0.2-0.7
Albumin (g/dL)	4.9	3.5-5.5
AST (U/L)	36	0-38
ALP (U/L)	46	0-41
Gama GT (U/L)	224	11–50
Alkaline phosphatase(U/L)	87	21-85
Total cholesterol (mg/dL)	246	0-200
HDL cholesterol (mg/dL)	90	35 or greater
Triglycerides (mg/dL)	65	0-150
Amylase (U/L)	1451	60-180
Lipase (U/L)	19	0-160
Alpha-fetoprotein 1 (ng/mL)	49	0-15
CA 19-9 (U/mL)	Less than 2.5	0-30
T3 (ng/mL)	122	60-181
T4 (µg/mL)	10.2	4.5-10.9
TSH (µU/mL)	1.949	0.5-4.7

The abdominal ultrasonography showed no pancreatic abnormalities but showed two stones (about 3 and 5 mm) in both kidneys. MRI showed pancreas with normal texture and dimension.

The patient then underwent pancreatic arteriography and splenoportography in order to analyze the amylase concentrations of the head, body and tail of the pancreas (Figure 1). No differences were found between the amylase and lipase concentrations in the three different collection points (splenic hilum, head and body of the pancreas). The results are shown in Table 3. She has been followed up for more than two years with no symptoms at all.

Figure 1. Splenic vein venography. A catheter is placed inside the splenic vein after transhepatic portal vein catheterization. Blood samples are obtained in the three sections of the pancreas (tail, body, and head).

Table 3. Amylase and lipase concentrations during the splenoportography in three different pancreatic portions.
	Amylase (U/L)	Lipase (U/L)
Splenic hilum and pancreas tail	730	32.3
Pancreas body	726	38.9
Pancreas head	712	31.8

DISCUSSION

cases of hyperamylasemia associated with pancreatic diseases are common in clinical practice. This dysfunction can also occur in situations such as kidney failure, brain trauma, traumatic shock, postoperative diabetic acidosis, renal transplants, pneumonia, pregnancy, prostate disease, mesenteric thrombosis and macroamylasemia.

However, when this serum amylase increase presents unrelated to other hyperenzymemias and with no significant symptoms, we should investigate the patient’s clinical history in order to assess a possible association between this increase and systemic diseases (Figure 2) [9], and also investigate the family history for familiar hyperamylasemia.

Figure 2. Flow chart for diagnosis of pancreatic hyperamylasemia with or without symptoms. (Modified from Frulloni et al. [9]).

To characterize this disorder as chronic pancreatic or no pathological hyperenzymemia is also important to determine the behavior of this increase of pancreatic enzymes in a given space of time, as through a study of 42 patients with this syndrome [14], who had followed serum pancreatic enzymes concentrations for 5 consecutive days and had demonstrated that concentrations of these enzymes varied widely, including the periods of stabilization. In all 37 cases with available data abnormal high enzyme concentrations were associated with increase of the lipase and trypsin concentrations. In only three patients, the serum amylase was the only enzyme with high abnormal concentration. Furthermore, Gullo [14] advises that the benign pancreatic hyperenzymemia diagnosis can only be given after an observation period of with no symptoms and/or signs of pancreatic diseases and no structural changes of the organ during this period of time. Other authors [15, 16] have reported cases of families who had recorded extremely high levels of amylase which persisted for several generations without other symptoms.

This condition was called familiar hyperamylasemia, which was consistent with autosomal dominant inheritance pattern and genetics as a cause of this disorder. However, the most controversial debates are about the pancreatic steatosis. Gullo et al. [17] used magnetic resonance imaging to exclude this hypothesis as the cause of hyperamylasemia. Cavallini et al. [18] supported this hypothesis, because they found a significant increase in pancreatic echogenicity (considered as an index of pancreatic steatosis) in 80% of patients with hyperamylasemia compared with 29% of patients in the control group. Therefore, the literature has still not reached a consensus about the real cause of this syndrome.

The present patient had normal pancreatic texture both at ultrasonography and magnetic resonance. According to Hellerhoff et al. [19], i.v. administration of secretin induces the secretion of fluid and bicarbonate by the exocrine pancreas. Thus, ductal filling is increased, and visualization of the pancreatic tract is improved. Under such circumstances, Testoni et al. [20] supported that MRI with secretin stimulation is a known factor able to increase the detection of pancreatic duct abnormalities that may be associated with hyperenzymemia. However, it is not clear how these pancreatic ductal abnormalities can explain the high serum levels of pancreatic enzymes.

This test was not performed in the present case because it was not available in our center. The confirmation that all regions of the pancreas revealed high levels of pancreatic enzyme may exclude ductal abnormalities as the reason for hyperamylasemia.

In conclusion, the correct diagnosis of silent hyperamylasemia is important in order to determine whether there is the risk of pancreatic disease or if we are just ahead of a benign hyperenzymemia. Since CNPH shows no clinical consequences and had not a specific treatment, we should always alert to any symptoms.

Received September 10^th, 2012 – Accepted October 16^th, 2012

Key words Hyperamylasemia, Pancreas

Abbreviations CNPH: chronic pancreatic non-pathological hyperenzymemia

Conflicts of interest The authors have no potential conflict of interest

Correspondence
Julio Cesar Wiederkehr
Rua da Paz, 195; Sala 508
80060-160 Curitiba-PR
Brazil
Phone: +55-41.9972.5887
Fax: +55-41.3018.8745
E-mail: julio.wieder@uol.com.br

References

1. Mortelé, K. J., Wiesner, W., Zou, K. H., Ros, P. R., & Silverman, S. G. (2004). Asymptomatic nonspecific serum hyperamylasemia and hyperlipasemia: spectrum of MRCP findings and clinical implications. Abdominal imaging, 29(1),109-14.

2. Yadav D, Nair S, Norkus EP, Pitchumoni CS (2000) Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterology 95:3123–3128.

3. Vissers RJ, Abu-Laban RB, McHugh DF (1999) Amylase and lipase in the emergency department: evaluation of acute pancreatitis. J Emerg Med 17:1027–1037.

4. Gullo L (1996) Chronic nonpathological hyperamylasemia of pancreatic origin. Gastroenterology 110:1905–1908.

5. Heikius B, Niemela S, Lehtola J, Karttunen TJ (1999) Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterology 94:1062–1069.

6. Pezzilli R, Andreone P, Morselli-Labate AM, et al. (1999) Serum pancreatic enzyme concentrations in chronic viral liver diseases. Dig Dis Sci 44:350–355.

7. Martinez J, Gomez A, Palazon JM, et al. (1997) Asymptomatic chronic hyperamylasemia of unknown origin: an infrequent entity?. Gastroenterology 112:1057.

8. Forsmark CE, Baillie J; AGA Institute Clinical Practi- ce and Economics Committee; AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis.Gastroenterology. 2007;132(5):2022-44.

9. Frulloni, L., Patrizi, F., Bernardoni, L., & Cavallini, G. (2005). Pancreatic hyperenzymemia: clinical significance and diagnostic approach. JOP : Journal of the pancreas, 6(6), 536-51.

10. Castiglione F, Del Vecchio Blanco G, Rispo A, Mazzacca G. Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine. Am J Gastroenterol 2000; 95:2394-5.

11. Gullo L, Ventrucci M, Barakat B, Migliori M, Tomassetti P, Pezzilli R. Effect of secretin on serum pancreatic enzymes and on the Wirsung duct in chronic nonpathological pancreatic hyperenzymemia. Pancreatology 2003;3:191-4.

12. Cook LJ, Musa OA, Case RM. Intracellular transport of pancreatic enzymes. Scand J Gastroenterol 1996;31(suppl. 219):1-5.

13. Gelaye, B., Bekele, T., Khali, a, Haddis, Y., Lemma, S., Berhane, Y., & Williams, M. a. (2011). Laboratory reference values of complete blood count for apparently healthy adults in Ethiopia. Clinical laboratory, 57(7-8),635-40.

14. Gullo L. benign pancreatic hyperenzymemia. Digestive and liver disease 2007;39:698-702.

15. Cuckow PM, Foo AY, Jamal A ET al. Familial hyperamylasemia. Gut 1997;40:689-690.

16. Koda YKL, Vidolin E. Familial hyperamylasemia. Rev Hosp Clín Med S Paulo 2002;57(2):77-82.

17. Gullo L, Salizzoni E, SerraC, Calculli L, Bastagli L, Migliori M. Can pancreatic steatosis explain the finding of pancreatic hyperenzymemia in subjects with dyslipidemia? Pancreas 2006;33:351-3.

18. Cavallini G, Frulloni L, Vaona B, Di Francesco V, Bovo P. Is hyperamylasemia related to dyslipidemia? Gastroenterology 1997;112:1058-9.

19. Hellerhoff, K. J., Iii, H. H., Rösch, T., Settles, M. R., Link, T. M., & Rummeny, E. J. (2002). After Secretin Administration : Image Quality and Diagnostic Accuracy, (July), 121–129.

20. Testoni PA, Mariani A, Curioni S, Giussani A, Masci E. Pancreatic ductal abnormalities documented by secretin-enhanced MRCP in asymptomatic subjects with chronic pancreatic hyperenzymemia. Am J Gastroenterol 2009; 104:1780-6.